deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04217421

Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass (CRUCIAL)

Sponsor: ACE Pharmaceuticals BV

Conditions Congenital Heart Disease in Children Neuroprotection
Interventions Allopurinol Mannitol
Updated 7 times since 2020 Last updated: May 13, 2024 Started: Feb 14, 2020 Primary completion: Oct 31, 2026 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Congenital Heart Disease in Children and Neuroprotection and is currently actively recruiting participants. ACE Pharmaceuticals BV leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotRecruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotRecruiting~May 2022 – ~Jul 2023 · 14 months · monthly snapshotRecruiting~Jul 2023 – ~Jun 2024 · 11 months · monthly snapshotUnknown Status~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – present · 22 months · monthly snapshotRecruiting

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  3. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

    Status: Unknown Status → Recruiting

  4. Jul 2023 — Jun 2024 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  5. May 2022 — Jul 2023 [monthly]

    Recruiting PHASE3

▶ Show 2 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Recruiting PHASE3

  2. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ACE Pharmaceuticals BV
  • Erasmus Medical Center
  • University Medical Center Groningen
  • University Medical Center Nijmegen
  • ZonMw: The Netherlands Organisation for Health Research and Development
  • dr. M.J.N.L. Benders
Data source: UMC Utrecht

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations